GenEdit is sailing toward the clinic with a new name and fresh funding.  | GenEdit is sailing toward the clinic with a new name and fresh funding. Rebranded as BreezeBio, the biotech has raised $60 ...

Sanofi has kicked off its preparations for the 2026 World Cup by becoming an official backer of Boston’s involvement in the soccer showcase. | Sanofi has kicked off its preparations for the 2026 World ...

A coalition of 15 states is filing a lawsuit against Robert F. Kennedy Jr. | A coalition of 15 states is filing a lawsuit against Robert F. Kennedy Jr. and the Centers for Disease Control and ...

Since BridgeBio scored FDA approval for cardiomyopathy drug Attruby 15 | When BridgeBio presented its quarterly report on Tuesday, it laid out expectations on the potential threat of generic pricing ...

In 2006, Gilead Sciences and Bristol Myers Squibb left a permanent mark on the HIV treatment paradigm by fusing together three antiretrovirals and creating the ...

Following the release of the first swath of results from a pharma- and he | In developing media plans to reach the GLP-1-interested consumer, audio advertising may represent a “blind spot,” according ...

Novartis is wasting little time sketching out the radiopharmaceutical details of its $23 billion U.S. investment push. | Novartis is wasting little time sketching out the radiopharmaceutical details ...

AstraZeneca is giving Pascal Soriot a pay raise as the longtime CEO weathered a year of “significant geopolitical uncertainty ...

Amid efforts on several fronts to improve the affordability of its GLP-1 medications for diabetes and obesity, Novo Nordisk is taking a new approach by aiming straight for semaglutide’s list price. | ...

Four years after the FDA issued its most heavy-handed form of a rejection to the prior company behind pegzilarginase, the U.S. regulator has now given the treatment a thumbs-up. | Four years after the ...

Still, broad uptake has long been an uphill battle for the gene therapy as it competes with a variety of treatments including, Roche’s blockbuster Hemlibra, Sanofi’s newer sales driver Altuviiio and ...

The agreement ends litigation between the Swiss company and the estate of Henrietta Lacks, which filed a lawsuit in federal court in Baltimore against Novartis and Viatris in August 2024. The family ...